Price
Financials
Consolidated, Rs crore| Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 158 | 187 | 197 | 26 | 18 | 1 | 2 | 5 | 3 | 3 | 4 | 2 |
| Expenses | 134 | 141 | 184 | 65 | 39 | 16 | 27 | 39 | 21 | 22 | 16 | 375 |
| Operating Profit | 24 | 46 | 13 | -40 | -21 | -15 | -25 | -34 | -19 | -19 | -11 | -373 |
| OPM % | 15% | 25% | 6% | -155% | -114% | -1,104% | -1,411% | -752% | -676% | -611% | -264% | -18,034% |
| Other Income | 14 | 8 | 21 | 33 | 17 | 40 | 56 | 44 | 53 | 38 | 1,865 | 59 |
| Interest | 10 | 10 | 11 | 1 | 2 | 1 | 4 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 9 | 10 | 4 | 1 | 1 | 2 | -0 | 1 | 2 | 1 | 1 | 1 |
| Profit before tax | 18 | 34 | 18 | -8 | -7 | 22 | 27 | 8 | 32 | 17 | 1,852 | -316 |
| Tax % | 30% | 37% | 24% | -276% | -91% | 1% | -20% | -121% | -17% | -16% | 1% | 1% |
| Net Profit | 10 | 19 | 12 | -70 | -1 | 22 | 32 | 19 | 37 | 19 | 1,840 | -317 |
| EPS in Rs | 1.91 | 3.53 | 2.20 | -12.84 | -0.11 | 4.03 | 5.94 | 3.40 | 6.77 | 3.52 | 337.24 | -58.17 |
| Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Mar 2015 15m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 743.52 | 752.34 | 740.49 | 767.36 | 667.76 | 799.76 | 133.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 510.97 | 514.86 | 494.25 | 502.55 | 521.49 | 661.69 | 267.16 | 10.64 | 25.19 | 12.47 | 1.46 | 0.31 |
| Operating Profit | 232.55 | 237.48 | 246.24 | 264.81 | 146.27 | 138.07 | -134.00 | -10.64 | -25.19 | -12.47 | -1.46 | -0.31 |
| OPM % | 31.28% | 31.57% | 33.25% | 34.51% | 21.90% | 17.26% | -100.63% | |||||
| Other Income | 9.23 | 16.46 | 15.33 | 10.29 | 78.76 | 103.71 | 80.99 | 120.14 | 42.57 | 7.63 | 0.46 | 0.04 |
| Interest | 53.26 | 46.75 | 55.43 | 65.05 | 52.19 | 48.26 | 5.48 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 44.81 | 46.72 | 54.68 | 74.27 | 65.35 | 49.05 | 3.86 | 0.14 | 0.10 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 143.71 | 160.47 | 151.46 | 135.78 | 107.49 | 144.47 | -62.35 | 109.36 | 17.28 | -4.84 | -1.00 | -0.27 |
| Tax % | 9.28% | 11.86% | 16.64% | 23.47% | 20.54% | -8.45% | -36.74% | -0.51% | 9.90% | 54.75% | 401.00% | 0.00% |
| Net Profit | 130.37 | 141.44 | 126.25 | 103.91 | 84.41 | 149.48 | -39.44 | 109.93 | 15.56 | -7.49 | -5.01 | -0.27 |
| EPS in Rs | 22.16 | 19.78 | 16.28 | 13.23 | 27.39 | -7.23 | 20.15 | 3.12 | -1.37 | -0.92 | -0.05 | |
| Dividend Payout % | 7.85% | 9.02% | 10.11% | 12.28% | 68.05% | 0.00% | -27.67% | 9.93% | 64.20% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | % | % | % | ||
| Compounded Profit Growth | % | 14% | % | 95% | ||
| Stock Price CAGR | 5% | % | % | % | ||
| Return on Equity | % | % | % | % |
| Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 34.12 | 63.82 | 63.82 | 63.82 | 63.82 | 54.57 | 54.57 | 54.57 | 54.57 | 54.57 | 54.57 | 54.57 |
| Reserves | 476.08 | 851.17 | 988.29 | 1,085.05 | 1,340.48 | 1,262.14 | 864.94 | 965.37 | -53.86 | -60.94 | -65.96 | -66.23 |
| Borrowings | 314.01 | 360.63 | 408.64 | 542.09 | 267.78 | 533.82 | 598.73 | 21.56 | 0.00 | 0.00 | 20.97 | 21.01 |
| Other Liabilities | 531.62 | 418.91 | 269.86 | 311.34 | 438.84 | 333.25 | 229.06 | 740.65 | 23.31 | 28.10 | 0.40 | 0.43 |
| Total Liabilities | 1,355.83 | 1,694.53 | 1,730.61 | 2,002.30 | 2,110.92 | 2,183.78 | 1,747.30 | 1,782.15 | 24.02 | 21.73 | 9.98 | 9.78 |
| Fixed Assets | 492.03 | 530.60 | 663.27 | 870.60 | 571.57 | 1,074.29 | 866.17 | 56.41 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 123.23 | 233.57 | 41.92 | 174.27 | 173.29 | 2.83 | 10.42 | 2.40 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.02 | 0.02 | 0.02 | 0.02 | 818.32 | 533.92 | 308.28 | 291.26 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 740.55 | 930.34 | 1,025.40 | 957.41 | 547.74 | 572.74 | 562.43 | 1,432.08 | 24.02 | 21.73 | 9.98 | 9.78 |
| Total Assets | 1,355.83 | 1,694.53 | 1,730.61 | 2,002.30 | 2,110.92 | 2,183.78 | 1,747.30 | 1,782.15 | 24.02 | 21.73 | 9.98 | 9.78 |
| Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 380.80 | 69.67 | -18.93 | 334.18 | 143.38 | -41.43 | 20.46 | 179.35 | -5.82 | -0.15 | 6.17 | -0.11 |
| Cash from Investing Activity | -103.81 | -191.86 | -221.22 | -436.61 | 197.01 | -122.86 | 56.80 | -58.46 | -133.48 | 0.35 | 0.41 | 0.05 |
| Cash from Financing Activity | -56.95 | 280.86 | -24.20 | 58.27 | -342.88 | 152.21 | 22.28 | -105.49 | -13.14 | 0.00 | -6.67 | -0.01 |
| Net Cash Flow | 220.04 | 158.67 | -264.35 | -44.16 | -2.49 | -12.07 | 99.54 | 15.41 | -152.44 | 0.21 | -0.09 | -0.06 |
| Free Cash Flow | 279.12 | -126.44 | -253.43 | -108.85 | 924.15 | -258.70 | -90.95 | 108.80 | 3.18 | -0.15 | 6.17 | -0.11 |
| CFO/OP | 182% | 39% | -1% | 136% | 110% | 6% | -40% | -2,440% | 12% | 1% | -41% | 35% |
| Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 129.98 | 119.54 | 135.04 | 108.56 | 85.55 | 104.58 | 458.91 | |||||
| Inventory Days | 202.51 | 236.25 | 227.47 | 268.54 | 66.44 | 96.51 | 337.48 | |||||
| Days Payable | 268.75 | 207.26 | 107.34 | 156.09 | 110.97 | 130.52 | 518.84 | |||||
| Cash Conversion Cycle | 63.74 | 148.52 | 255.17 | 221.01 | 41.02 | 70.57 | 277.55 | |||||
| Working Capital Days | 11.65 | 81.48 | 199.37 | 152.54 | -62.96 | 71.29 | 336.30 | |||||
| ROCE % | 26.23% | 19.78% | 15.17% | 12.74% | 8.29% | 9.95% | -1.23% | 8.54% | 1.92% | -62.31% | -2.85% |
| Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | |
|---|---|---|---|---|---|---|---|
| Promoters | 60.99% | 52.56% | 50.13% | 50.13% | 50.13% | 50.13% | 50.13% |
| FIIs | 20.29% | 25.43% | 25.86% | 26.48% | 26.22% | 25.62% | 26.02% |
| DIIs | 1.35% | 1.35% | 1.49% | 1.86% | 1.86% | 1.94% | 1.94% |
| Public | 17.36% | 20.66% | 22.52% | 21.53% | 21.79% | 22.31% | 21.91% |
| No. of Shareholders | 20,983 | 20,549 | 20,117 | 19,659 | 18,198 | 17,902 | 17,032 |
Fundamentals
Market Cap₹ 2,164 Cr.
Current Price₹ 397
Book Value₹ -2.14
ROCE-2.85 %
ROE%
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)%
Compounded Profit Growth (TTM)95%
Consolidated figures.
Valuation
P/B, 3-year average-238.42x
P/E, 5-year average71.60x
P/B, 5-year average466.84x
Profitability
EBITDA margin12999.92%
Pre-tax margin12930.61%
Net profit margin12889.88%
Net margin, latest quarter-15334.78%
ROE2.34%
ROCE-2.85%
ROA-2.73%
ROE, 3-year average107.81%
ROCE, 3-year average-32.58%
ROA, 3-year average-22.36%
ROE, 5-year average67.62%
ROCE, 5-year average-13.32%
ROA, 5-year average-11.79%
ROIC (approx.)17897.63%
Other income / net worth-0.34%
Growth
Sales growth QoQ-51.97%
Profit growth QoQ-117.25%
Sales growth YoY (latest quarter)-54.51%
Profit growth YoY (latest quarter)-1809.37%
Per share
EPS (TTM)Rs 289.37
EPS (latest year)Rs -0.05
EPS (latest quarter)Rs -58.17
EPS, 3-year averageRs -0.78
EPS, 5-year averageRs 4.18
Book value per shareRs -2.14
Sales per shareRs 2.24
Cash flow per shareRs -0.02
Free cash flow per shareRs -0.02
Dividend per share, 5-year averageRs 2.00
Dividends
Dividend payout, 5-year average37.05%
Efficiency
Creditor days519 days
Cash conversion cycle278 days
Working capital days336 days
Leverage
Total debtRs 21 Cr
Cash and bankRs 0 Cr
Net debtRs 21 Cr
Debt to equity-1.80x
Net debt / EBITDA0.01x
Interest coverage451.00x
Owners' fund to total sources-119.22%
Debt to assets214.83%
Cash flow
Cash from Operating Activity (latest year)Rs -0 Cr
Cash from Investing Activity (latest year)Rs 0 Cr
Cash from Financing Activity (latest year)Rs -0 Cr
Net Cash Flow (latest year)Rs -0 Cr
Free cash flow (latest year)Rs -0 Cr
FCFE (approx.: FCF + change in debt)Rs -0 Cr
Cash from ops / profit, 5 years1.59x
Statement figures
Net sales (TTM)Rs 12 Cr
Sales (latest quarter)Rs 2 Cr
Operating profit (latest quarter)Rs -373 Cr
Other income (TTM)Rs 2,015 Cr
EBITDA (TTM)Rs 1,592 Cr
PBDT (TTM)Rs 1,589 Cr
Profit before tax (TTM)Rs 1,584 Cr
Net profit (TTM)Rs 1,579 Cr
Net profit (latest year)Rs -0 Cr
Net profit (latest quarter)Rs -317 Cr
Depreciation (TTM)Rs 5 Cr
Depreciation (latest quarter)Rs 1 Cr
Interest (TTM)Rs 4 Cr
Cost of goods sold (latest year)Rs 0 Cr
Total income (latest year)Rs 0 Cr
Share capitalRs 55 Cr
ReservesRs -66 Cr
Shareholders' fundsRs -12 Cr
Total assetsRs 10 Cr
Other liabilitiesRs 0 Cr
Shares outstanding (crore)5.46
Ownership
Promoter holding50.13% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.
Red flags
F-score 3 of 6| serious | Negative equity Shareholders' equity is negative |
| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Dec 2017Sales ₹2 Cr -60.0% vs Dec 2016.
Net loss ₹317 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Claris Lifesciences Ltd?
Claris Lifesciences Ltd (533288) has a market capitalisation of Rs 2,164 Cr. at the close.
What were Claris Lifesciences Ltd's latest quarterly results?
In the Dec 2017 quarter, Claris Lifesciences Ltd sales was Rs 2 Cr (-60.0% vs Dec 2016) with a net loss of Rs 317 Cr.